Vincristine sulfate is under clinical development by Assertio Therapeutics and currently in Phase III for Non-Hodgkin Lymphoma. According to GlobalData, Phase III drugs for Non-Hodgkin Lymphoma have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Vincristine sulfate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vincristine sulfate overview
Vincristine sulfate (Marqibo) is a vinca alkaloid acts as an anti-neoplastic agent. Marqibo is vincristine encapsulated in sphingomyelin/cholesterol liposomes and follows Lipid Nanoparticle (LNP) drug delivery system. It is formulated as liposomal suspension for intravenous route of administration. Marqibo was indicated for the treatment of adult patients with philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more treatment lines of anti-leukemia therapy.
See Also:
Vincristine sulfate (Marqibo) is under development for the treatment of front-line aggressive non-Hodgkin lymphoma and adult Philadelphia negative (Ph-) acute lymphocytic leukemia (ALL). It is developed based on Optisome technology. The therapeutic candidate is administered through intravenous route. It acts by targeting tubulin. It was under development for the treatment of metastatic uveal melanoma, relapsed and refractory acute myeloid leukemia (AML) and acute lymphocytic leukemia.
Assertio Therapeutics overview
Assertio Therapeutics, a subsidiary of Assertio Holdings Inc, is a pharmaceutical company that develops products for neurological diseases. The company is headquartered in Lake Forest, Illinois, the US.
For a complete picture of Vincristine sulfate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
